At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Intravenous Ketaminedrug
Likely dose
Intravenous Ketamine 0.5mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Repeated Neurocognitive Measurements in Depressed Patients
In Brief
A Phase 2 clinical trial evaluating Intravenous Ketamine for Depression, Unipolar. Completed, enrolled 15 participants across 1 site.
Detailed Summary
In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Unipolar
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartSep 2021
Primary CompletionJul 2023
Study CompletionAug 2023
TodayJul 2026
First PostedJun 7, 2021
Enrollment StartSep 16, 2021
Primary CompletionJul 15, 2023
Study CompletionAug 15, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.1 years ago
Interventions
Intravenous Ketaminedrug
Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)